Dendritic cell survivin vaccine (H Lee Moffitt Cancer Center and Research Institute)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameDendritic cell survivin vaccine (H Lee Moffitt Cancer Center and Research Institute)

Drug Alias NameDC-AdmS

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesH Lee Moffitt Cancer Center & Research Institute

China Registration ClassN/A

Develop Information

Active CompaniesH Lee Moffitt Cancer Center & Research Institute

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A